Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC M WEAVER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1265621544
CMS profile
193713
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,079.88

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,079.88 56

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC M WEAVER

NPI 1265621544 · CMS profile ID 193713

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265621544?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC M WEAVER, NPI 1265621544, CMS profile ID 193713. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265621544?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ERIC M WEAVER, NPI 1265621544, CMS profile ID 193713. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265621544?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ERIC M WEAVER, NPI 1265621544, CMS profile ID 193713, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1265621544?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $1,079.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–56 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Advanced Respiratory, Inc $13.8402/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853544403 CMS
Janssen Pharmaceuticals, Inc $11.6302/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788052381 CMS
United Therapeutics Corporation $32.0002/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839124051 CMS
GlaxoSmithKline, LLC. $27.7502/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801703151 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.6002/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763667596 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2401/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763667598 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,664.45 64
PY2020 $606.77 34
PY2021 $1,079.88 56
PY2022 $1,741.01 72
PY2023 $1,781.23 75
PY2024 $2,003.82 65
PY2025 $2,777.44 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $195,622.24 70
PY2024 Principal investigator $196,231.64 54
PY2023 Principal investigator $70,972.24 14
PY2022 Principal investigator $17,704.00 1
PY2019 Recipient $2,237.93 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,556.48 12/24/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384663
Principal investigator 1 United Therapeutics Corporation $1,556.48 12/24/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384691
Principal investigator 1 United Therapeutics Corporation $1,937.92 12/24/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384701
Principal investigator 1 United Therapeutics Corporation $390.00 12/10/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384719
Principal investigator 1 United Therapeutics Corporation $3,975.50 12/10/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384741
Principal investigator 1 United Therapeutics Corporation $3,772.45 12/02/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384641
Principal investigator 1 United Therapeutics Corporation $1,392.64 11/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384661
Principal investigator 1 United Therapeutics Corporation $3,409.92 11/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384679
Principal investigator 1 United Therapeutics Corporation $1,392.64 11/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384687
Principal investigator 1 United Therapeutics Corporation $704.00 11/12/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384653
Principal investigator 1 United Therapeutics Corporation $4,587.52 11/12/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384681
Principal investigator 1 United Therapeutics Corporation $1,747.20 11/12/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384697
Principal investigator 1 United Therapeutics Corporation $1,937.92 11/12/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384699
Principal investigator 1 United Therapeutics Corporation $4,587.52 11/12/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384713
Principal investigator 1 United Therapeutics Corporation $10,071.75 11/07/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384745
Principal investigator 1 United Therapeutics Corporation $2,800.20 11/03/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384737
Principal investigator 1 United Therapeutics Corporation $450.00 09/05/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384617
Principal investigator 1 United Therapeutics Corporation $600.00 09/05/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384619
Principal investigator 1 United Therapeutics Corporation $1,303.00 09/05/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384627
Principal investigator 1 United Therapeutics Corporation $1,908.00 09/05/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384633
Principal investigator 1 United Therapeutics Corporation $12,375.00 09/05/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384643
Principal investigator 1 United Therapeutics Corporation $3,248.64 08/27/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384677
Principal investigator 1 United Therapeutics Corporation $1,908.40 08/22/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384725
Principal investigator 1 United Therapeutics Corporation $2,500.00 08/06/2025 Non-covered Recipient Entity
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242388587
Principal investigator 1 United Therapeutics Corporation $25,170.00 08/06/2025 Non-covered Recipient Entity
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242388589
Principal investigator 1 United Therapeutics Corporation $390.00 08/01/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384717
Principal investigator 1 United Therapeutics Corporation $1,949.35 08/01/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384727
Principal investigator 1 United Therapeutics Corporation $2,242.00 08/01/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384729
Principal investigator 1 United Therapeutics Corporation $2,027.52 07/23/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384703
Principal investigator 1 United Therapeutics Corporation $11,713.00 07/23/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384747
Principal investigator 1 United Therapeutics Corporation $2,949.12 07/08/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384675
Principal investigator 1 United Therapeutics Corporation $2,949.12 07/08/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384707
Principal investigator 1 United Therapeutics Corporation $2,385.92 06/25/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384671
Principal investigator 1 United Therapeutics Corporation $3,128.32 06/25/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384709
Principal investigator 1 United Therapeutics Corporation $450.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384615
Principal investigator 1 United Therapeutics Corporation $1,303.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384625
Principal investigator 1 United Therapeutics Corporation $2,428.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384637
Principal investigator 1 United Therapeutics Corporation $2,457.60 06/11/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384673
Principal investigator 1 United Therapeutics Corporation $2,457.60 06/11/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384705
Principal investigator 1 United Therapeutics Corporation $2,352.20 05/29/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384635
Principal investigator 1 United Therapeutics Corporation $84.50 05/14/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384715
Principal investigator 1 United Therapeutics Corporation $1,170.00 05/14/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384723
Principal investigator 1 United Therapeutics Corporation $2,337.40 05/14/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384733
Principal investigator 1 United Therapeutics Corporation $450.00 05/08/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384613
Principal investigator 1 United Therapeutics Corporation $1,105.00 05/08/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384621
Principal investigator 1 United Therapeutics Corporation $1,303.00 05/08/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384623
Principal investigator 1 United Therapeutics Corporation $2,428.00 05/08/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384639
Principal investigator 1 United Therapeutics Corporation $1,107.20 05/07/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384657
Principal investigator 1 United Therapeutics Corporation $1,392.64 05/07/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384659
Principal investigator 1 United Therapeutics Corporation $2,027.52 05/07/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384667
Principal investigator 1 United Therapeutics Corporation $2,027.52 05/07/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384669
Principal investigator 1 United Therapeutics Corporation $1,747.20 05/07/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384695
Principal investigator 1 United Therapeutics Corporation $1,420.25 05/05/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384629
Principal investigator 1 United Therapeutics Corporation $1,392.64 04/23/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384685
Principal investigator 1 United Therapeutics Corporation $3,255.04 04/23/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384711
Principal investigator 1 United Therapeutics Corporation $819.20 04/09/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384655
Principal investigator 1 United Therapeutics Corporation $819.20 04/09/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384683
Principal investigator 1 United Therapeutics Corporation $1,472.00 04/09/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384689
Principal investigator 1 United Therapeutics Corporation $2,337.40 03/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384731
Principal investigator 1 United Therapeutics Corporation $1,495.00 03/06/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242384631
Principal investigator 1 United Therapeutics Corporation $5,916.16 02/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384647
Principal investigator 1 United Therapeutics Corporation $1,937.92 02/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384649
Principal investigator 1 United Therapeutics Corporation $1,638.40 02/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384665
Principal investigator 1 United Therapeutics Corporation $1,638.40 02/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384693
Principal investigator 1 United Therapeutics Corporation $780.00 02/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384721
Principal investigator 1 United Therapeutics Corporation $6,042.40 02/26/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384743
Principal investigator 1 United Therapeutics Corporation $2,805.40 02/21/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384739
Principal investigator 1 United Therapeutics Corporation $2,703.36 02/12/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384645
Principal investigator 1 United Therapeutics Corporation $2,800.20 02/03/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242384735
Principal investigator 1 United Therapeutics Corporation $2,703.36 01/29/2025 Non-covered Recipient Entity
CENTER FOR BIOMEDICAL RESEARCH
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242384651